Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLOLIPID vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Reduction of elevated total-C, LDL-C, Apo B, and TG and to increase HDL-C in patients with primary hyperlipidemia (Fredrickson type IIa and IIb) or mixed dyslipidemia,Reduction of elevated TG in patients with hypertriglyceridemia (Fredrickson type IV),Treatment of primary dysbetalipoproteinemia (Fredrickson type III) when diet is not sufficient,Reduction of total-C and LDL-C in patients with homozygous familial hypercholesterolemia,Prevention of cardiovascular events in patients with high risk of coronary heart disease
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 3 to 4 hours; however, due to extensive enterohepatic recirculation, the clinical duration of action is longer, allowing for once-daily dosing.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Simvastatin is a prodrug; the lactone ring is hydrolyzed in vivo to the active β-hydroxyacid form. It is extensively metabolized by CYP3A4 and also undergoes glucuronidation. Major metabolites include the active β-hydroxyacid and 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily hepatic metabolism with biliary excretion; approximately 90% of the dose is recovered in feces, and less than 10% in urine, mainly as metabolites.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
More than 99% bound, primarily to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 0.4 L/kg, indicating distribution into extravascular tissues; not extensively bound to tissues.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is not applicable as Flolipid is an intravenous lipid emulsion; bioavailability is 100% via intravenous route.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For GFR 30 to <60 m L/min/1.73 m²: maximum dose 2 mg once daily. For GFR <30 m L/min/1.73 m²: not recommended.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. No specific Child-Pugh-based dosing adjustments provided; use with caution in mild hepatic impairment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For patients 8 years and older with heterozygous familial hypercholesterolemia: 2 mg orally once daily; may increase to 4 mg once daily after 4 weeks.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No dose adjustment required; monitor for increased risk of myopathy and renal function in patients over 65 years.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Simvastatin is contraindicated for use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone) and with gemfibrozil, cyclosporine, or danazol. Do not exceed 20 mg simvastatin daily with amiodarone, amlodipine, or ranolazine. Do not exceed 40 mg simvastatin daily with lomitapide or diltiazem. Avoid grapefruit juice. Increased risk of myopathy/rhabdomyolysis with these drugs.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Myopathy/Rhabdomyolysis: Risk factors include age >65 years, female, renal impairment, uncontrolled hypothyroidism, and concomitant use of certain drugs (see Black Box Warning).,Hepatic effects: Persistent elevations in serum transaminases; recommend liver enzyme monitoring before and during treatment.,Increased risk of diabetes mellitus: Small increase in fasting glucose and Hb A1c.,Interstitial lung disease: Rare cases reported.,Use with caution in patients with predisposing factors for renal impairment.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to any component of Flolipid,Active liver disease or unexplained persistent elevations of serum transaminases,Concomitant use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone),Concomitant use of gemfibrozil, cyclosporine, or danazol,Pregnancy and breastfeeding,Women of childbearing potential unless using effective contraception
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Grapefruit juice may modestly increase pitavastatin exposure; limit to small amounts (≤8 oz per day). No other significant food interactions; can be taken with or without food. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotoxicity. Second and third trimesters: Statins may reduce fetal cholesterol synthesis; risk of fetal harm cannot be excluded. Use only if pregnancy risk accepted.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Breastfeeding is contraindicated during rosuvastatin therapy. M/P ratio: unknown. Rosuvastatin is excreted in rat milk; human data absent. Potential for serious adverse reactions in nursing infants.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
FLOLIPID should be discontinued upon pregnancy detection. No dose adjustments in pregnancy as use is contraindicated. Pharmacokinetic changes in pregnancy may reduce rosuvastatin exposure, but safety data insufficient to recommend resuming.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Flolipid (pitavastatin) is a potent statin with minimal CYP metabolism, reducing drug interactions; monitor for myopathy and hepatotoxicity; avoid in active liver disease; dose adjustment needed with renal impairment (Cr Cl <30 m L/min); no significant food effect, but grapefruit juice may modestly increase exposure; consider in patients with statin intolerance due to fewer CYP-mediated interactions.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take Flolipid at the same time each day, with or without food.,Avoid consuming large amounts of grapefruit juice; a small glass (8 oz) is acceptable.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you develop jaundice, dark urine, or abdominal pain (signs of liver problems).,Continue a heart-healthy diet and exercise while taking this medication.,Do not double the dose if you miss one; take the next dose at the usual time.,Inform your doctor of all other medications, including over-the-counter drugs and supplements.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLOLIPID vs ABSTRAL, answered by our medical review team.
FLOLIPID is a HMG-CoA Reductase Inhibitor (Statin) that works by Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLOLIPID and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLOLIPID is: Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLOLIPID and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLOLIPID is classified as Category C. FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotox. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.